Chlamydia Trachomatis

Chlamydia is the quiet one. It often produces no symptoms at all, yet left undetected it can climb upward from the cervix into the uterus and fallopian tubes, scarring tissue and quietly setting the stage for pelvic pain, ectopic pregnancy, and infertility years later. A vaginal swab tests for the bacterium directly at the site of infection.

This test looks for genetic material from Chlamydia trachomatis (the bacterium that causes chlamydia) using a vaginal swab you can collect yourself. The result tells you whether the organism is currently present in your genital tract, with accuracy that beats urine testing and matches or exceeds what a clinician swab from the cervix would find.

What This Test Actually Measures

Modern chlamydia testing uses a method called a nucleic acid amplification test (NAAT), which detects DNA or RNA from the bacterium itself. The vaginal swab collects cells and secretions from the genital tract, where the bacterium lives and multiplies inside the cells lining the cervix, vagina, urethra, and uterus. A positive result reflects an active infection. The result is qualitative, reported as positive or negative rather than as a level.

This is fundamentally different from a chlamydia antibody blood test, which looks for your immune system's memory of past exposure. A swab tells you whether the bacterium is in your body right now. An antibody test tells you whether your body has seen it before. The two are not interchangeable.

Why It Matters: Pelvic Inflammatory Disease and Infertility

Untreated chlamydia is a leading preventable cause of infertility in women. In a Dutch cohort of women previously tested for chlamydia, those who tested positive had significantly higher rates of pelvic inflammatory disease and tubal factor infertility compared with women who tested negative. A separate analysis using prospective data estimated that annual screening for chlamydia could prevent roughly 61% of pelvic inflammation in women, with risk concentrated in the first weeks after infection.

What this means for you: the damage that chlamydia causes is largely silent. By the time scarring affects fertility, the original infection has often cleared on its own or been forgotten. Catching it on a swab, while it can still be treated with a short course of antibiotics, is the only way to interrupt that cascade.

Pregnancy and Newborn Outcomes

Chlamydia during pregnancy is linked to preterm delivery. A meta-analysis pooling multiple studies found that chlamydia infection during pregnancy was associated with about 2.3 times the risk of preterm delivery compared with uninfected pregnancies. Genital infections during pregnancy have also been linked to low birth weight and neonatal pneumonia.

A review of antenatal screening studies found that 13 out of 15 studies supported the idea that screening and treating chlamydia during pregnancy may reduce adverse outcomes for both mother and baby. Treatment with the most common single-dose antibiotic for chlamydia in pregnancy left nearly 1 in 4 pregnancies with persistent or recurrent infection when retested about 30 days later, which is why a follow-up test after treatment matters.

Cervical and Ovarian Cancer Associations

Chlamydia detection has been linked to cervical changes that can precede cancer. In a study of women attending fertility and gynecology clinics, the presence of chlamydia DNA was strongly associated with cervical intraepithelial neoplasia, a precancerous change in the cervix.

A possible link between chlamydia and ovarian cancer has also been investigated, but the evidence remains mixed and the association is still considered uncertain. In the European EPIC cohort, women with serological signs of past chlamydia exposure showed a connection to certain subtypes of ovarian cancer (serous and mucinous) but not to overall epithelial ovarian cancer risk. A separate analysis pooling two independent populations found that antibodies against chlamydia (Pgp3) were associated with a roughly doubled ovarian cancer risk, while a more recent 2026 study found no association with epithelial ovarian cancer, only with borderline ovarian tumors. A meta-analysis estimated only a modest 1.34-fold increased risk with significant heterogeneity across studies. The biological idea, that pelvic inflammation from chlamydia could contribute to ovarian cancer over time, is plausible but not established.

Why a Vaginal Swab Beats a Urine Test

Many clinics still test for chlamydia using a urine sample because it feels easier and less invasive. The evidence consistently shows this practice misses cases. A meta-analysis comparing the two specimens found that vaginal swabs detected chlamydia with 94.1% sensitivity, while urine detected it with 86.9% sensitivity. That gap of roughly 7 percentage points translates into a meaningful number of infected women going undiagnosed when urine is used instead of a swab.

Self-collected vaginal swabs perform just as well as swabs collected by a clinician. Across multiple studies and NAAT platforms, self-collected swabs typically show sensitivities in the 96 to 99% range with specificities at or above 98%, although performance varies by assay and at least one platform (the cobas 4800) has reported sensitivity closer to 85%. In one emergency department study, self-obtained swabs had 95% sensitivity and were highly acceptable to patients.

Source: Aaron et al. meta-analysis (2023); Schachter et al. APTIMA multicenter evaluation (2005); Chinnock et al. emergency department study (2021).

What this means for you: if you are choosing how to test, a vaginal swab is the most accurate option, and you can collect it yourself without losing accuracy.

Confirming Cure and Why One Test Is Often Not Enough

This is not a trend you track over years like cholesterol. Chlamydia testing is event-driven: you test when you might have been exposed, when you have symptoms, when you have a new partner, or when you are screening on a regular cadence as part of sexual health care. But within a single episode of infection, repeat testing matters.

After treatment, a test of cure performed several weeks later confirms that the antibiotic worked. In pregnant women treated with single-dose azithromycin, about 23% of pregnancies showed persistent or recurrent chlamydia when retested at about 30 days. Even outside pregnancy, reinfection from an untreated partner is common, which is why guidelines recommend retesting roughly three months after treatment to catch new infection.

For ongoing sexual health monitoring, annual screening is a reasonable baseline for sexually active women under 25 and for anyone with new or multiple partners, with more frequent testing for those at higher risk or whose partners have not been notified and treated.

What to Do With an Unexpected Result

A positive vaginal swab is actionable. The current first-line treatment is doxycycline 100 mg twice daily for 7 days, which clears genital infection in roughly 95 to 100% of cases and clears rectal infection far more reliably than single-dose azithromycin. If you test positive, the decision pathway includes treating partners from at least the last 60 days, abstaining from sex until you and your partner(s) have completed treatment, and retesting in about three months to detect reinfection.

A positive result on a vaginal swab also raises the question of testing other anatomic sites. If you have had receptive anal or oral sex, urogenital testing alone misses a meaningful share of infections. Rectal and pharyngeal swabs are needed to fully clear those sites. Co-testing for gonorrhea, trichomoniasis, and other STIs at the same time is standard.

When Results Can Be Misleading

A single NAAT on a properly collected vaginal swab is highly reliable, but a few situations can distort the result:

• Testing too soon after exposure: the bacterium takes time to produce enough genetic material to be detectable. The incubation period is roughly 7 to 21 days, so testing within the first one to two weeks after exposure can produce a falsely negative result (the CDC does not specify a formal window period for chlamydia NAAT). If exposure is recent and your test is negative, retesting a few weeks later is sensible.
• Testing too soon after treatment: NAATs detect bacterial DNA or RNA, which can persist for several weeks after the organism is dead. A test of cure performed within four weeks of finishing antibiotics can show a positive result that does not reflect active infection. The CDC recommends waiting at least 4 weeks before testing for cure by NAAT.
• Specimen handling: delays in transport and warm storage temperatures can degrade the bacterial DNA in the sample. Vaginal samples are more robust than urine in this regard, but following the kit's transport instructions matters.
• Rare diagnostic-avoiding variants: a small number of chlamydia strains carry mutations that evade certain commercial assays. This is uncommon, but if you have strong symptoms and a negative result, retesting on a different platform is reasonable.

Co-Infections and Companion Testing

Chlamydia rarely travels alone. It is frequently found alongside gonorrhea, trichomoniasis, Mycoplasma genitalium, and human papillomavirus, particularly in younger women. A positive chlamydia result is a strong cue to make sure the rest of a routine STI workup is current, including testing for gonorrhea on the same swab, plus HIV, syphilis, and hepatitis B serology if not recently done.